You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

SINGAPORE & SAN DIEGO--(BUSINESS WIRE)--ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced the formation of its Scientific Advisory Board (SAB). The SAB is composed of leading scientists in immunology and oncology who will help to guide ImmunoScapes scientific strategy. ImmunoScapes Deep Immunomics platform enables the characterization of a patients immunome at ultra-high resolution. This technology reveals the immune system in action by directly observing the modulation of phenotype, function, and specificity of individual immune cells, at scale and over time. These insights can be provided to leading biopharma and academic partners to aid drug development efforts within multiple therapeutic areas, including immuno-oncology, infectious disease, and autoimmune disease. The founding members of the SAB bring substantial scientific insight and expertise to assist the company. The founding members of the SAB include: To form this scientific advisory board, we brought together key thought leaders within immunology, across academia and industry alike, said Michael Fehlings, Ph.D., Director of Scientific Affairs at ImmunoScape. All of their careers have centered around developing next generation immunotherapies by gaining a greater understanding of immune cell function and responses. Their work has paved the way for ImmunoScapes technology to have a greater impact, and their guidance will be invaluable as we look to further our development and commercialization efforts. The future of immunotherapy development depends upon an enhanced ability to observe and analyze the T cell immune response at high resolution, said Phil Greenberg, MD. ImmunoScapes platform represents a leap forward in this capability, rapidly providing insights into reasons for success or failure, and therefore has profound implications for this entire field of medicine. I am delighted to work with the SAB and with the companys senior scientists in further advancing this technology. To learn more about ImmunoScapes scientific advisory board and its technology, please visit https://immunoscape.com/. About ImmunoScape ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution. The company's Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, and visualization tools to provide novel, reproducible immune profiling information. This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets. For more information, please visit https://immunoscape.com/.

Answer: ImmunoScape Establishes Scientific Advisory Board of Distinguished Immunology Experts World-class scientists and physicians from Fred Hutchinson Cancer Research Center, St. Jude Childrens Research Hospital, Massachusetts General Hospital and Harvard Medical School, will provide unique research perspectives and strategic direction